An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)

NCT ID: NCT04876313

Last Updated: 2022-04-06

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 29 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-01-27
• Study Completion Date: 2025-06-30

Brief Summary

To assess whether nivolumab+nab-paclitaxel combination results in patients with muscle-invasive bladder cancer

Detailed Description

This is a Phase 2, single-center, open-label, non-randomized study in patients with muscle-invasive urothelial carcinoma of the bladder.

The general framework of the study will be as follows:

A transurethral resection of the bladder for biopsy, histological characterization, and local staging will be executed first. With the aim to improve the sensitivity of CT scan in assessing pelvic lymph-nodes and better assess the local extent of bladder tumor, computed tomography (CT) scan, 18FDG-PET/CT scan, and multiparametric bladder MRI (mpMRI) will be done during screening and before cystectomy to stage and evaluate response.

Eligible patients will receive neoadjuvant treatment: 360 mg nivolumab IV on Day 1 plus 125 mg/m2 nab-paclitaxel on Day 1 and 8, in a 21-day cycle.

A total of 4 cycles are planned before surgery. Surgery will be planned at the time of study inclusion to be done within 3 weeks of the last dose of study drug.

Dose reductions will be applied depending on the severity of AEs, and treatment interruption or discontinuation criteria will be fully described in the protocol.

After surgery, patients will receive 12-month adjuvant therapy with nivolumab 360 mg IV, every 3 weeks.

RECIST v1.1 criteria will be used to assess patient response to treatment by determining tumor size and PFS. Screening assessments should be performed no more than 21 days prior to the start of study treatment. Following the screening assessment, subsequent assessments will be carried out after the administration of the study drugs prior to cystectomy. If an unscheduled assessment is performed and the patient has not progressed, the results should be reported at the next scheduled visit. The method of tumor assessment used at baseline e.g. CT or MRI scans chest, abdomen, pelvis, must be used at each sub-sequent follow-up assessment.

Patients will be monitored carefully for the development of adverse events and will be monitored for clinical and/or radiographic evidence of disease progression according to usual standards of clinical practice. Adverse experiences will be evaluated according to criteria outlined in the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.

Conditions

Muscle-Invasive Bladder Carcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Combined Drugs

Participants received 4x3 weekly cycles of 360 mg Nivolumab + 125 mg/m\^2 Nab-paclitaxel IV on days 1 and 8, then they had cystectomy after that partecipants received adjuvant nivolumab 360 mg IV Q3W X13 cycles

Group Type: EXPERIMENTAL

Nivolumab + Nab-paclitaxel

Intervention Type: DRUG

4x3 weekly cycles of 360 mg nivolumab + 125 mg/m\^2 nab-paclitaxel IV on days 1 and 8

Nivolumab

Intervention Type: DRUG

360 mg IV Q3W x 13 cycles

Interventions

Nivolumab + Nab-paclitaxel

4x3 weekly cycles of 360 mg nivolumab + 125 mg/m\^2 nab-paclitaxel IV on days 1 and 8

Intervention Type: DRUG

Nivolumab

360 mg IV Q3W x 13 cycles

Intervention Type: DRUG

Other Intervention Names

Nivolumab + Abraxane; Adjuvant Nivolumab

Eligibility Criteria

Inclusion Criteria

• Female or male subjects, >18 years of age, able to understand and give written informed consent.
• Histopathologically confirmed urothelial carcinoma. Patients with mixed histologies are required to have a dominant (i.e. 50% at least) transitional cell pattern.
• Fit and planned for RC (according to local guidelines).
• ECOG performance status score of 0 or 1.
• Adequate hematologic counts without transfusional or growth factor support within 2 weeks of study drug initiation (Hemoglobin ≥ 9 g/dL, ANC ≥ 1,500/ mm3, and Platelets ≥ 100,000/ μL).
• Adequate hepatic function (Bilirubin ≤ 1.5 IULN, AST and ALT ≤ 2.5 x IULN or ≤ 5 x IULN if known liver metastases and serum albumin >3 g/dl).
• Creatinine clearance ≥30 mL/min as assessed by the Cockcroft-Gault equation.
• Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication, and must not be lactating. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
• Female subjects of childbearing potential must be willing to use 2 methods of birth control or be surgically sterile or abstain from heterosexual activity for the course of the study through 4 months after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for >2 years.
• Male subjects must agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study therapy.
• Clinical stage T2-T4aN0M0 MIBC, assessed by CT + PET/CT + mpMRI.
• The patient accepts to undergo RC.
• Ineligibility to receive cisplatin-based neoadjuvant chemotherapy based on Galsky's criteria (Galsky MD, et al. J Clin Oncol. 2011 Jun 10;29(17):2432-8) OR refusal to receive neoadjuvant cisplatin-based chemotherapy.

Exclusion Criteria

• Has received prior systemic anti-cancer therapy including investigational agents and immunotherapy.
• Prior immunotherapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137.
• Has received prior radiotherapy on the bladder tumor.
• Have received a partial cystectomy.
• Refusal to undergo RC.
• Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.
• Has received any antibiotics within 30 days prior to the first dose of study drug.
• Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.

Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.

• Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
• Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded. Participants with low-risk early stage prostate cancer defined as follows are not excluded; Stage T1c or T2a with a Gleason score ≤ 6 and prostatic-specific antigen (PSA) < 10 ng/mL either treated with definitive intent or untreated in active surveillance that has been stable for the past year prior to study allocation.
• Has severe hypersensitivity (≥Grade 3) to nivolumab or nab-paclitaxel and/or any of its excipients.
• Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
• Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
• Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of enrollment
• Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
• Have active cardiac disease, defined as:

• Myocardial infarction or unstable angina pectoris within 6 months of C1D1
• History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication); history of QT interval prolongation
• NYHA Class III or greater congestive heart failure or left ventricular ejection fraction of < 40%
• Have known history of HIV-1/2 infection.
• Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection.
• Have other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
• High dose systemic corticosteroids (≥20 mg of prednisolone or its equivalent) are not allowed within 2 weeks of C1D1.
• Have received or are currently receiving (within the previous 2 weeks) antibiotics.
• Have a pre-existing motor or sensory neuropathy of a severity >= grade 2 by NCI-CTC criteria due to the potential for neuropathy of nab-paclitaxel.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Bristol-Myers Squibb

INDUSTRY

Sponsor Role: collaborator

IRCCS San Raffaele

OTHER

Sponsor Role: lead

Responsible Party

Prof. Andrea Necchi

Associate Professor - Head of Genitourinary Medical Oncology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Genitourinary Medical Oncology - IRCCS San Raffaele Hospital and Scientific Institute

Milan, MI, Italy

Site Status: RECRUITING

Countries

Italy

Central Contacts

Andrea Necchi

Role: CONTACT

necchi.andrea@hsr.it

+39 0226435789

Rossella Miotti

Role: CONTACT

Miotti.rossella@hsr.it

+39 0226435789

Facility Contacts

Andrea Necchi

Role: primary

necchi.andrea@hsr.it

+39 0226435789

Rossella Miotti

Role: backup

Miotti.rossella@unisr.it

+39 0226435789

References

Mercinelli C, Moschini M, Cigliola A, Mattorre B, Tateo V, Basile G, Cogrossi LL, Maiorano BA, Patane DA, Raggi D, Pastorino GL, Re C, Colecchia M, Luciano R, Colombo R, Brembilla G, De Cobelli F, Briganti A, Pavlick DC, Ross JS, Montorsi F, Bellone M, Necchi A. First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer. J Clin Oncol. 2024 Dec 10;42(35):4196-4205. doi: 10.1200/JCO.24.00576. Epub 2024 Sep 6.

Reference Type: DERIVED

PMID: 39241203 (View on PubMed)

Other Identifiers

2020-005050-20

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

NURE-Combo

Identifier Type: -

Identifier Source: org_study_id